FIELD: medicine; oncology; therapy.
SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology and therapy; it is intended for the treatment of estrogen-receptor-positive breast cancer in a subject who needs it. The treatment method includes administration to the specified subject of therapeutically effective amount of MPS1 inhibitor, wherein the specified subject was previously treated with an endocrine therapy drug, and/or the specified breast cancer is resistant to endocrine therapy. Applications of MPS1 inhibitor for the treatment of estrogen-receptor-positive breast cancer in a subject and for the production of a drug for the treatment of estrogen-receptor-positive breast cancer in a subject are also presented.
EFFECT: use of the group of inventions provides effective treatment of estrogen-receptor-positive breast cancer.
84 cl, 19 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| BENZOPYRAZINE AND BENZOXEPINE PI3K INHIBITORS AND USE THEREOF | 2009 |
|
RU2506267C2 |
| 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-RICH REPEATING KINASE 2 (LRRK2) FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2647849C2 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2016 |
|
RU2695337C2 |
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| AKT ACTIVITY INHIBITORS | 2006 |
|
RU2421454C2 |
| DIAMINOTRIAZOLES, SUITABLE AS INHIBITORS OF PROTEIN KINASES | 2003 |
|
RU2350606C2 |
